An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians’ Perspective
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians’ Perspective
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-04-12
DOI
10.3389/fphar.2021.655054
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis
- (2020) Silvio Danese et al. Clinical Gastroenterology and Hepatology
- Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
- (2020) William J. Sandborn et al. GASTROENTEROLOGY
- Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease
- (2020) William J. Sandborn et al. GASTROENTEROLOGY
- Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
- (2020) Harry Sokol et al. Microbiome
- Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program
- (2020) William J. Sandborn et al. ADVANCES IN THERAPY
- TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User’s Guide: An Update
- (2020) Marianne Vulliemoz et al. DIGESTION
- Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
- (2020) Brian G Feagan et al. Lancet Gastroenterology & Hepatology
- Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology
- (2020) Alexander Khoruts et al. Nature Reviews Gastroenterology & Hepatology
- Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update
- (2020) Pufang Tan et al. Frontiers in Pharmacology
- Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-based Data
- (2019) Stephanie Coward et al. GASTROENTEROLOGY
- DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study
- (2019) L Peyrin-Biroulet et al. Journal of Crohns & Colitis
- DOP48 Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study
- (2019) G D’Haens et al. Journal of Crohns & Colitis
- Colitis ulcerosa: Kann eine Modulation der intestinalen Mikrobiota eine langfristige Remission bedingen?
- (2019) Andreas Stallmach et al. ZEITSCHRIFT FUR GASTROENTEROLOGIE
- Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
- (2019) William J. Sandborn et al. GASTROENTEROLOGY
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Mucosal Healing, Clinical Response and Clinical Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From the Open-Label Extension Study TURANDOT II
- (2019) Silvio Danese et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis
- (2019) William J. Sandborn et al. GASTROENTEROLOGY
- Mongersen (GED-0301) for Active Crohnʼs Disease
- (2019) Bruce E. Sands et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study
- (2017) Bruce E. Sands et al. GASTROENTEROLOGY
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
- (2017) Brian G Feagan et al. LANCET
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
- (2016) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis
- (2015) Naoki Yoshimura et al. GASTROENTEROLOGY
- Briakinumab for Treatment of Crohnʼs Disease
- (2015) Remo Panaccione et al. INFLAMMATORY BOWEL DISEASES
- Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
- (2014) Séverine Vermeire et al. LANCET
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started